Wu W - Search Results

1

Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer.

Shi S, Guo D, Ye L, Li T, Fei Q, Lin M, Yu X, Jin K, Wu W. Shi S, et al. Among authors: wu w. Cell Death Dis. 2023 Nov 27;14(11):778. doi: 10.1038/s41419-023-06313-x. Cell Death Dis. 2023. PMID: 38012214 Free PMC article.

2

Focus on mast cells in the tumor microenvironment: Current knowledge and future directions.

Shi S, Ye L, Yu X, Jin K, Wu W. Shi S, et al. Among authors: wu w. Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188845. doi: 10.1016/j.bbcan.2022.188845. Epub 2022 Dec 5. Biochim Biophys Acta Rev Cancer. 2023. PMID: 36476563 Review.

3

Tissue-resident CXCR4⁺ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression.

Liao Z, Ye L, Li T, Jin X, Lin X, Fei Q, Zhang H, Shi S, Yu X, Jin K, Wu W. Liao Z, et al. Among authors: wu w. Int J Cancer. 2023 Jun 1;152(11):2396-2409. doi: 10.1002/ijc.34468. Epub 2023 Feb 21. Int J Cancer. 2023. PMID: 36757203

4

Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer.

Liu C, Deng S, Xiao Z, Lu R, Cheng H, Feng J, Shen X, Ni Q, Wu W, Yu X, Luo G. Liu C, et al. Among authors: wu w. Discov Oncol. 2023 Feb 17;14(1):20. doi: 10.1007/s12672-023-00628-z. Discov Oncol. 2023. PMID: 36797531 Free PMC article.

5

Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer.

Guo D, Ye L, Wu W, Yu X, Jin K. Guo D, et al. Among authors: wu w. Acta Biochim Biophys Sin (Shanghai). 2023 Apr 6;55(6):923-937. doi: 10.3724/abbs.2023045. Acta Biochim Biophys Sin (Shanghai). 2023. PMID: 37021976 Free PMC article. Review.

6

Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma.

Jin KZ, Wu Y, Zheng XX, Li TJ, Liao ZY, Fei QL, Zhang HR, Shi SM, Sha X, Yu XJ, Chen W, Ye LY, Wu WD. Jin KZ, et al. Among authors: wu y, wu wd. FEBS J. 2023 Sep;290(18):4577-4590. doi: 10.1111/febs.16879. Epub 2023 Jun 10. FEBS J. 2023. PMID: 37245155 Free article.

7

Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma.

Li TJ, Jin KZ, Zhou HY, Liao ZY, Zhang HR, Shi SM, Lin MX, Chai SJ, Fei QL, Ye LY, Yu XJ, Wu WD. Li TJ, et al. Cancer Lett. 2023 Nov 1;576:216411. doi: 10.1016/j.canlet.2023.216411. Epub 2023 Sep 26. Cancer Lett. 2023. PMID: 37757903

8

Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway.

Fei Q, Jin K, Shi S, Li T, Guo D, Lin M, Yu X, Wu W, Ye L. Fei Q, et al. Among authors: wu w. Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):513-524. doi: 10.3724/abbs.2023286. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38229544 Free PMC article.

9

The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer.

Zhang HR, Li TJ, Yu XJ, Liu C, Wu WD, Ye LY, Jin KZ. Zhang HR, et al. Cell Death Dis. 2024 Apr 4;15(4):244. doi: 10.1038/s41419-024-06589-7. Cell Death Dis. 2024. PMID: 38575607 Free PMC article.

10

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer.

Shi S, Ye L, Jin K, Yu X, Guo D, Wu W. Shi S, et al. Among authors: wu w. Comput Struct Biotechnol J. 2024 Oct 5;23:3634-3650. doi: 10.1016/j.csbj.2024.09.032. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 39469671 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30,758 results

Search Page

Filters